Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > August 31, 2022
Daily News
August 31, 2022
- JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
August 31, 2022
- JPMA Urges Govt to Expand Support to Boost Competitiveness of Japan Pharma Industry
August 31, 2022
- BMS, Nagoya University Tie Up for Innovative Drug Discovery
August 31, 2022
- Eisai Files New Injection Formulation of Fycompa in Japan
August 31, 2022
- University of Tokyo Selected as Flagship R&D Site to Orchestrate Japan’s Vaccine Efforts: SCARDA Project
August 31, 2022
- Novo Seeks Japan Approval of Hemophilia Drug Concizumab
August 31, 2022
- Allocate All Savings from Off-Year Drug Re-Pricing to Medical Fees: Hodanren
August 31, 2022
- Viatris Launches Japan PIII to Add GAD Indication for Effexor SR
August 31, 2022
- Taiho’s GIST Drug Jeselhy Now Available in Japan
August 31, 2022
- Daiichi Sankyo Files Vanflyta for Frontline AML in Japan
August 31, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…